Potential conditions causing impairment of selective hepatobiliary enhancement of gadobenate dimeglumine-enhanced delayed magnetic resonance imaging.
OBJECTIVE
To identify conditions that might impair the delayed selective hepatobiliary enhancement of gadobenate dimeglumine.


METHODS
Ninety-five gadobenate-enhanced magnetic resonance imaging studies were retrospectively and independently analyzed. The effects of selective hepatic enhancement and biliary excretion were each categorized into 3 grades according to the perceived difference of signal intensity between the liver parenchyma and portal vein, and signal intensity in the common bile duct of precontrast- and delayed-phase images.History of diffuse liver disease, liver cirrhosis, and renal disease; elevated levels of blood urea nitrogen (BUN)/creatinine (Cr), aspartate aminotransferase (AST)/alanine aminotransferase, bilirubin, and alkaline phosphatase (ALP); ascites; and splenomegaly were compared according to the grade of hepatic and biliary enhancement.


RESULTS
Diffuse liver disease (P = 0.002); cirrhosis (P < 0.001); renal disease (P = 0.022); ascites (P = 0.001); splenomegaly (P < 0.001); and elevated levels of BUN (P = 0.001), Cr (P = 0.003), AST (P < 0.001), bilirubin (P < 0.001), and ALP (P < 0.001) were factors that impaired selective hepatic enhancement. Biliary excretion was affected by the presence of liver disease (P < 0.001), cirrhosis (P < 0.001), splenomegaly (P < 0.001), ascites (P = 0.002), and elevated levels of Cr (P = 0.013), AST (<0.001), alanine aminotransferase (P = 0.001), bilirubin (P < 0.001), and ALP (P < 0.001).


CONCLUSIONS
Delayed selective hepatobiliary enhancement of gadobenate dimeglumine can be impaired by liver or renal disease and/or by elevated levels of bilirubin, ALP, BUN, and Cr.
Kim
Honsoul
H
Department of Radiology, Yonsei University Health System, Seoul, Republic of Korea.
Kim
Myeong-Jin
MJ
Park
Mi-Suk
MS
Cha
Seung-Whan
SW
Lim
Joon Seok
JS
Yoo
Hyung Sik
HS
Kim
Ki Whang
KW
D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001659:Biliary Tract / Q000378:metabolism*; D001663:Bilirubin / Q000097:blood; D001806:Blood Urea Nitrogen; D003287:Contrast Media / Q000493:pharmacokinetics*; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D007674:Kidney Diseases / Q000378:metabolism; D008099:Liver / Q000378:metabolism*; D008107:Liver Diseases / Q000378:metabolism; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008536:Meglumine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D008875:Middle Aged; D015588:Observer Variation; D009942:Organometallic Compounds / Q000493:pharmacokinetics*; D012189:Retrospective Studies; D013163:Splenomegaly / Q000378:metabolism
D003287:Contrast Media; D009942:Organometallic Compounds; C064572:gadobenic acid; D008536:Meglumine; D003404:Creatinine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D001663:Bilirubin